engleski

Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources.

Soft tissue sarcomas (STS) are rare tumors with more than 50 histologic subtypes. Treatment outcomes for patients with STS has improved over the past few decades mostly due to the adoption of a multidisciplinary approach, but still patients with advanced disease have a poor prognosis.Our study compared efficacy of novel sarcoma therapies - pazopanib and trabectedin vs standard chemotherapy, after failure to anthracycline based therapy, in patients with metastatic STS

soft tissue sarcoma ; systemic treatment ; pazopanib ; trabectedin

nije evidentirano